Why do countries have different attitudes towards hydroxychloroquine? Will the dark horse finally appear here?

Although on March 27, the Official Response of the World Health Organization stated that there was no valid evidence that chloroquine and hydroxychloroquine had a preventive or therapeutic effect on COVID-19, while high-dose use of chloroquine and hydroxychloroquine could trigger serious adverse reactionsBut this does not prevent the global heat on the treatment of chlorquins for COVID-19chloroquine/hydroxychloroquine as an old antimalarial drug, but also used to treat lupus, rheumatoid arthritis and other autoimmune diseases, with safety, low cost and other advantagesHowever, the existing research on chloroquine/hydroxychloroquine to treat new coronary pneumonia is mostly a small range of non-randomized controlled studies of small sample size, and there is a lack of rigorous clinical research evidenceis noteworthy that as of April 1, 19 studies worldwide had applied for chloroquine/hydroxychloroquine for clinical trials to treat COVID-19Whether chloroquine/hydroxychloroquine will be what MrTrump calls a "turnaround" in treating new coronary pneumonia will be answered01.China: Since the sixth edition, chloroquine has been included in the national version of the diagnosis and treatment program
as early as February 19, the National Health and Health Commission issued the "new coronavirus pneumonia treatment plan (trial sixth edition)" removed from the previous program "there is currently no confirmed effective anti-new coronavirus treatment." "And in the trial drug, the addition of "chlorpyrifos phosphate and Abidor" two drugsIn order to ensure the safety of medication, on 28 February, the National Health And Health Commission adjusted the use of chloroquine phosphate for the treatment of neo-coronary pneumonia, especially for patients weighing less than 50 kg, reducing the use of chloroquine phosphate"chloroquine is not a special medicine, but an effective drugZhong Nanshan, head of the high-level expert group of the National Health and Health Commission and a member of the Chinese Academy of Engineering, said in an interview with CCTV that the new drug development cycle is too long, and the advantage of the old drug is its safety, which can be verified quickly"As long as it's not harmful after it's used, you can try it." "
02.France: Provisional approval of chloroquine/hydroxychloroquine for new coronary treatment
On 28 March, the French Government officially approved chloroquine/hydroxychloroquine for the treatment of new coronary pneumonia"This means that not only are previously routine medications available for continued use, but also are provisionally approved for the treatment of some patients with new coronary pneumonia." "The head of the General Health Department of the French Ministry of Health, J?r?me Salomon, saidThe move comes after French infectious disease specialist Didier Raoult published an article saying the latest findings showed that 80 patients with neo-corolla and azithromycin were treated with a combination of hydroxychloroquine and azithromycin, with 78 patients effective within six days However, the study is still a non-randomized controlled study of small sample sizes, and the French government has indicated that a larger sample size will be conducted in the future 03.U.S.: Hydroxychloroquine has been widely used for practical treatment
On March 21st, the CDC on its official website announced the united States commonly used drugs for the treatment of patients with new coronary pneumonia, one is Ridsiewe, the other is chloroquine/hydroxychloroquine Unlike Chinese clinical solutions, the CDC in the United States prefers to use hydroxychloroquine because it has higher in vitro activity than chloroquine, and hydroxychloroquine is more accessible in the United States U.S President Donald Trump has pushed several times on his Twitter feed and briefing to push for the treatment of neoprene pneumonia March 28, the FDA issued an emergency use authorization (Emergency Use Authorization) that allows the distribution of hydroxychloroquine and chloroquine products donated to national strategic reserves to the states for clinical treatment of patients with new coronary pneumonia Although analysts point out that "emergency use authorization" does not imply inclusion in official treatment guidelines for drugs, hydroxychloroquine is currently more widely used in new lung treatments in the United States Three-quarters of the 1,400 new lung patients admitted to a New Jersey hospital were treated with hydroxychloroquine, FOX News reported mean by a randomized controlled trial conducted by the University of Minnesota on March 16, which plans to recruit 3,000 volunteers to evaluate the role of hydroxychloroquine in pre-exposure, post-exposure prophylaxis, and early intervention therapy for neo-coronaviruses A randomized controlled study of large sample sizes will hopefully provide sufficient evidence for an objective assessment of the effects of hydroxychloroquine 04.Italy: Started the large-scale application of hydroxychloroquine to clinical According to the Italian Evening Post on March 29, Italy began to use hydroxychloroquine for clinical treatment of new coronary pneumonia, initially in Rome, Lazio and other regions Italy, it explains, that every COVID-19 patient will be treated with hydroxychloroquine when they have early symptoms Italy's new coronary pneumonia death rate is high, according to the World Health Organization official data show that as of April 1, Italy confirmed 101,000 patients, 115,000 deaths, the fatality rate of 11.39 percent, far more than China, the United States and other countries new coronary pneumonia mortality rate (data source: WHO, watchmaking E drug manager) 05.UK: No approval for chloroquine treatment COVID-19 March 25, the Uk government's official website gov.uk issued a statement that chloroquine and hydroxychloroquine for COVID-19 prevention and treatment is not approved The UK government says there is no evidence that chloroquine and hydroxychloroquine can prevent or treat neo-corolla, and that previously, to ensure patient safety, the drug could only be used in clinical studies and not in practical treatment after a large-scale randomized, double-blind study of oxychloroquine prevention COVID-19, applied by Oxford University at ClinicalTrials.gov in the United States, has been controversial The study aims to recruit 40,000 volunteers at centres in Asia and Europe for three consecutive months of administration of chloroquine phosphate or hydroxychloroquine sulphate Sceptics say the need for prevention is questioned by the side effects of chloroquine/hydroxychloroquine and a three-month drug cycle original title: Why are hydroxychloroquine blown up by Trump differently? Will the dark horse finally appear here?